P2y12 inhibitors drugs

These studies compared monotherapy with a P2Y12 inhibitor versus aspirin for secondary prevention. However, in patients undergoing percutaneous coronary intervention, it is still unclear whether the efficacy of P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy depends on the type of P2Y12 inhibitor.

Outline Clinical uses Specific drugs (listing) - COX inhibitors (aspirin and other NSAIDs) - GPIIb/IIIa inhibitors - P2Y12 inhibitors

by JM Siller‐Matula 2024 Cited by 74Prasugrel and ticagrelor are novel P2Y12 receptor inhibitors. The thienopyridines clopidogrel and prasugrel act as irreversible oral inhibitors of the P2Y12

by R Koski 2024 Cited by 29Three oral P2Y12 inhibitors are available: clopidogrel, prasugrel, and ticagrelor (Brilinta, AstraZeneca). Clopidogrel, the first P2Y12 inhibitor, was the

Unable to tolerate P2Y12 inhibitors, such as clopidogrel, ticlopidine, ticagrelor, prasugrel, and cangrelor Antiplatelet drugs – P2Y12

Morphine Oral Solution is contraindicated in patients known to be hypersensitive to morphine sulfate (see section 4.3). Oral P2Y12 inhibitor antiplatelet therapy Within the first day of concomitant P2Y12 inhibitor and morphine treatment, reduced efficacy of P2Y12 inhibitor treatment has been observed (see section 4.5).

by R Koski 2024 Cited by 29Three oral P2Y12 inhibitors are available: clopidogrel, prasugrel, and ticagrelor (Brilinta, AstraZeneca). Clopidogrel, the first P2Y12 inhibitor, was the

by S MA Fayaz 2024 Cited by 3Keywords: Antiplatelet drugs, drug-drug interactions, P2Y12 inhibitors, pharmacogenetics, pharmacodynamics. P2Y12 RECEPTOR MEDIATED PLATELET AGGREGA-. TION.

Whether newer P2Y12 inhibitors are more efficacious and safer than clopidogrel and whether there is a superior one remain uncertain. We compared the effect of P2Y12 inhibitors on clinical outcomes